| Old Articles: <Older 7991-8000 Newer> |
|---|
 |
The Motley Fool
October 24, 2011
Brian Orelli |
Biotech Blunder Turned 20% Overnight Gain Exelixis gets good data, even if it wasn't exactly what it was expecting.   |
The Motley Fool
October 24, 2011 |
A Brief History of Pfizer's Returns At 14 times earnings, Pfizer looks reasonably valued, but not exactly cheap. |
The Motley Fool
October 22, 2011
Harsh Chauhan |
This Stock May Be a Surprisingly Good Buy Medtronic's moves could reap dividends in the future. |
The Motley Fool
October 21, 2011
Brian Orelli |
Full of News, but Worth a 15% Gain? Amylin serves up an appetizer. |
Chemistry World
October 21, 2011
Sarah Houlton |
Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns. |
The Motley Fool
October 20, 2011
Travis Hoium |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Shares of Cubist Pharmaceuticals jumped 10% today after the company released earnings. |
The Motley Fool
October 20, 2011
Travis Hoium |
Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news. |
The Motley Fool
October 20, 2011
Brian Orelli |
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. |
Pharmaceutical Executive
October 1, 2011 |
Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy. |
Pharmaceutical Executive
October 1, 2011 |
Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal. |
| <Older 7991-8000 Newer> Return to current articles. |
